Bearsville, NY – According to filings with the U.S. Securities and Exchange Commission, BAKX Therapeutics is raising $34,255,728.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sree Kant played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BAKX Therapeutics
We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations. We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis. We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients.

To learn more about BAKX Therapeutics, visit http://bakxtx.com/

Contact:
Sree Kant, Chief Executive Officer
718-419-5221
https://www.linkedin.com/in/sreekant/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved